Late last week a large prospective “study” showed that ivermectin was useless so it got headline reporting at the Wall Street Journal, unlike the other 80 controlled studies the newspaper ignored. This study is not even a peer reviewed paper, nor is it even news — The TOGETHER Trial announced results way back in August last year, but haven’t officially published the paper yet.

It’s a case of PR now, details later.

Thanks to the FLCCC we know some of the reasons the trial was never likely to succeed. And given that several groups involved in the trial were also big clients of Pfizer, it was a very convenient failure. Bear in mind, “fail” is relative — despite all the handicaps below, the Relative Risk of dying of Covid with low dose ivermectin was still 0.82 (0.44-1.52). Meaning they found a 20% lower mortality rate, but it wasn’t statistically significant when done with a low, late dose in the wrong way, with the wrong type of trial, with the wrong type of participants.

How to design a study to fail:

Click to enlarge.

Give the control group a head start. It helps to begin collecting data on […]